A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and
will be assessed for safety, tolerability, pharmacokinetics.
In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of
TQA3038 or placebo, administered subcutaneously (SC).